20 May 2021 
EMA/259161/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Libtayo 
cemiplimab 
On 20 May 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Libtayo. 
The marketing authorisation holder for this medicinal product is Regeneron Ireland Designated Activity 
Company (DAC). 
The CHMP adopted new indications as follows:2 
Cutaneous Squamous Cell Carcinoma 
Libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally 
advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for 
curative surgery or curative radiation. 
Basal Cell Carcinoma 
Libtayo as monotherapy is indicated for the treatment of adult patients with locally 
advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on 
or are intolerant to a hedgehog pathway inhibitor (HHI). 
Non-Small Cell Lung Cancer 
Libtayo as monotherapy is indicated for the first-line treatment of adult patients with 
non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no 
EGFR, ALK or ROS1 aberrations, who have: 
• 
locally advanced NSCLC who are not candidates for definitive chemoradiation, or  
•  metastatic NSCLC. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text as bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Libtayo  
EMA/259161/2021 
Page 2/2 
 
 
 
 
